Oral Inflammasome Inhibitors
  • IPF (idiopathic pulmonary fibrosis)
  • Ulcerative colitis
Optimization Pre-clinical ADMET/CMC Ph Ⅰ Ph Ⅱ
Ulcerative Colitis

Ulcerative Colitis is another indication whose pathology fits for Shaperon’s novel inflammasome inhibitors. With pre-clinical data all set for filing, we are planning phase I study for UC.

Shaperon’s HY209 controls GPCR19-P2X7 expressions, downregulates component proteins of NLRP3 inflammasome, suppresses inflammatory cytokines and infiltrating immune cells, repairs damaged intestinal tissue and improves diarrhea caused by ulcerative colitis

In DSS-induced UC mouse model, HY209 treatment shows a strong potency in the suppression of IL-1β, IL-6, TNF-α, reduction of diarrhea frequency, and repair of intestinal tissue in comparison with current standard of care treatment such as 5-ASA and Jak inhibitor.

  • Zaki et al., Trends Immunol. 2011 Apr;32(4):171-9